Literature DB >> 7483808

Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization.

J E Crowe1, P T Bui, G R Siber, W R Elkins, R M Chanock, B R Murphy.   

Abstract

A cold-passaged (cp) temperature-sensitive (ts) RSV mutant, designated RSV cpts-530, which possesses host-range mutations acquired during 52 passages at low temperature in bovine tissue culture and one or more ts mutations induced by chemical mutagenesis (shut-off temperature 39 degrees C) was found previously to be tenfold restricted in its replication in mice as compared to wild-type virus and stable genetically in nude mice. In the current study, we introduced additional attenuating mutations, such as small-plaque (sp) or ts mutations, into cpts-530 by chemical mutagenesis with 5-fluorouracil, with the intent of obtaining derivatives of cpts-530 that were more attenuated in mice or chimpanzees and that were more stable genetically following replication in vivo. Fourteen mutants of RSV cpts-530 which had acquired an additional ts mutation were identified and found to be more restricted in replication in BALB/c mice than the cpts-530 parental strain. One mutant, designated cpts-530/1009 (shut-off temperature 36 degrees C), was 30 times more restricted in replication in the nasal turbinates of mice and threefold more restricted in the nasopharynx of seronegative chimpanzees than its cpts-530 parent. Like its parent, this mutant was highly restricted (30,000-fold) in replication in the lower respiratory tract of chimpanzees even following direct intratracheal inoculation. The cpts-530 and cpts-530/1009 mutants exhibited a high level of stability of the ts phenotype during replication in chimpanzees.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7483808     DOI: 10.1016/0264-410x(94)00074-w

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  40 in total

1.  The major attenuating mutations of the respiratory syncytial virus vaccine candidate cpts530/1009 specify temperature-sensitive defects in transcription and replication and a non-temperature-sensitive alteration in mRNA termination.

Authors:  K Juhasz; B R Murphy; P L Collins
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 2.  Genetic and structural determinants of virus neutralizing antibodies.

Authors:  J E Crowe; R O Suara; S Brock; N Kallewaard; F House; J H Weitkamp
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

3.  The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein.

Authors:  K Juhasz; S S Whitehead; P T Bui; J M Biggs; J E Crowe; C A Boulanger; P L Collins; B R Murphy
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 4.  New generation live vaccines against human respiratory syncytial virus designed by reverse genetics.

Authors:  Peter L Collins; Brian R Murphy
Journal:  Proc Am Thorac Soc       Date:  2005

Review 5.  Recent vaccine development for human metapneumovirus.

Authors:  J Ren; T Phan; X Bao
Journal:  J Gen Virol       Date:  2015-02-09       Impact factor: 3.891

6.  Identification of an immunodominant neutralizing and protective epitope from measles virus fusion protein by using human sera from acute infection.

Authors:  S F Atabani; O E Obeid; D Chargelegue; P Aaby; H Whittle; M W Steward
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

7.  Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees.

Authors:  S S Whitehead; K Juhasz; C Y Firestone; P L Collins; B R Murphy
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

8.  Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene.

Authors:  J E Crowe; C Y Firestone; S S Whitehead; P L Collins; B R Murphy
Journal:  Virus Genes       Date:  1996       Impact factor: 2.332

9.  Recent advances in the study of human antibody responses to influenza virus using optimized human hybridoma approaches.

Authors:  James E Crowe
Journal:  Vaccine       Date:  2009-12-30       Impact factor: 3.641

10.  Inactivation of respiratory syncytial virus by zinc finger reactive compounds.

Authors:  Marina S Boukhvalova; Gregory A Prince; Jorge C G Blanco
Journal:  Virol J       Date:  2010-01-26       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.